Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activin pathway inhibitors are a class of molecules or drugs that block the activin signaling pathway, which is part of the larger transforming growth factor-beta (TGF-β) superfamily. These inhibitors work by preventing activins—protein complexes involved in cell proliferation, differentiation, and homeostasis—from binding to their receptors and activating downstream signaling.
Activin pathway inhibitors block the activin signaling pathway by preventing activins from binding to their receptors and activating downstream signaling. This can occur through various mechanisms, including binding directly to activins to neutralize them, blocking the extracellular domains of activin receptors, or inhibiting intracellular kinase activity associated with the pathway.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activin Pathway Inhibitor.